Roche’s CINtec PLUS Cytology Test Beneficial for Women at Higher Risk of Developing Cervical Cancer

Results from the IMPACT trial demonstrate a clear patient benefit from use of Roche’s CINtec PLUS Cytology dual-stain biomarker technology as a triage test for women positive for high-risk human papillomavirus (HPV). The data were established from a study of more than 35,000 women between 25 and 65 years of age, according to a Roche press release.

In the IMPACT trial, women who were positive for high-risk HPV received a follow-up triage test to help determine whether their cervical cells were transforming to cervical pre-cancer. The biomarker-based CINtec PLUS Cytology test showed a significantly higher sensitivity in detecting cervical pre-cancers compared to Pap cytology, according to Roche. Further, the test helps clinicians in more confidently determining which women are at an increased risk for high-grade cervical pre-cancer and require immediate further diagnostic procedures and which women may need repeat testing or routine screening, according to Roche.

"These latest results from the IMPACT trial confirm data from previous studies that show incorporating the CINtec PLUS Cytology test in cervical cancer screening programs can provide real benefits to both clinicians and their patients," said Thomas Wright, MD, professor Emeritus in Pathology and Cell Biology at Columbia University Medical Center, New York in a press release. "As a triage test for HPV-positive cervical cancer screening results, the CINtec PLUS Cytology test can be very useful to differentiate women who will benefit most from immediate referral to colposcopy from those women who can be followed up with less invasive methods.”

REFERENCE

IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer. Roche. October 29, 2021. Accessed November 1, 2021. https://www.roche.com/media/releases/med-cor-2021-10-29.htm